Clinical Trials Logo

Filter by:
NCT ID: NCT05403450 Active, not recruiting - Clinical trials for Relapsed/Refractory Peripheral T-cell Lymphoma

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Start date: June 23, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.

NCT ID: NCT05398445 Active, not recruiting - Atopic Dermatitis Clinical Trials

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

ROCKET-Ignite
Start date: May 31, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

NCT ID: NCT05395091 Active, not recruiting - Clinical trials for Osteoporosis, Postmenopausal

Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND

ALVOBOND
Start date: August 23, 2022
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, parallel design, repeat dose, 2 arm, multicenter study comparing the efficacy, safety, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of AVT03 and US-Prolia in postmenopausal women with osteoporosis.

NCT ID: NCT05394519 Active, not recruiting - Obesity Clinical Trials

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

REDEFINE 2
Start date: February 1, 2023
Phase: Phase 3
Study type: Interventional

This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

NCT ID: NCT05389449 Active, not recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Start date: October 28, 2022
Phase: Phase 3
Study type: Interventional

This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.

NCT ID: NCT05388669 Active, not recruiting - Clinical trials for Advanced or Metastatic Non-small Cell Lung Cancer

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

PALOMA-3
Start date: August 5, 2022
Phase: Phase 3
Study type: Interventional

The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.

NCT ID: NCT05384080 Active, not recruiting - Ulcerative Colitis Clinical Trials

A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

VARIETY
Start date: August 8, 2022
Phase:
Study type: Observational

The primary reason of this study is to observe current treatment options in participants receiving Vedolizumab, intravenous (IV) or subcutaneous (SC), for IBD in Poland. There is no treatment involved in this study, this is only an observational review of ongoing/initiating treatment data relating to Vedolizumab induction and maintenance treatment for IBD [including Ulcerative Colitis (UC) and Crohn's Disease (CD)].

NCT ID: NCT05377489 Active, not recruiting - Osteoarthritis Clinical Trials

Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee

Start date: August 26, 2022
Phase: Phase 3
Study type: Interventional

An open-label, single-arm clinical trial to confirm the safety of monoarticular injections or bi-lateral intra-articular injections of RTX-GRT7039 in patients who have pain associated with osteoarthritis of the knee despite standard of care.

NCT ID: NCT05368285 Active, not recruiting - Clinical trials for Chronic Spontaneous Urticaria

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Start date: May 19, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria

NCT ID: NCT05366855 Active, not recruiting - Clinical trials for Generalized Pustular Psoriasis

Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis

GEMINI2
Start date: April 21, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3, long term extension study to evaluate the safety and efficacy of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).